ASTrID

ASTrID® is a development platform for identification (ID) and antibiotic susceptibility testing (AST) of pathogens directly from blood – without the need for traditional blood culturing. ASTrID will be fully automated and easy to use, even for healthcare professionals outside the laboratory. Within four hours ASTrID will be able to identify the cause of sepsis and within an additional six hours deliver the antibiotic susceptibility profile. The pathogen ID panel will cover 95 percent of relevant pathogens including 33 unique pathogens and 10 pathogen groups, as well as 11 resistance markers. The panel of antibiotic substances will contain up to 48 antibiotics and bacterial growth or inhibition reported as Minimum inhibitory Concentration, MIC, values. The ASTrID platform is currently under development.

ASTrID can shorten the current lead times in sepsis treatment by 48 hours


ASTrID in short

  • Technology eliminating the need for traditional blood cultures
  • Broad panel, identifying 95 % of the bacteria that cause sepsis
  • “One-stop-shop” with the most comprehensive panel on the market
  • Fully automated and easy to use, even for healthcare professionals outside the laboratory

Please contact us for further specifications


Pathogen ID directly from blood

Clinical blood samples were collected from patients suspected of having sepsis attending the Infectious Disease ER at the University Hospital of Örebro. In addition to the standard 4 blood culture flasks drawn per patient for routine diagnostics, an extra flask was taken for this study.

Pathogen (E. coli, S. aureus, Staphylococcus spp., S. pneumoniae, C. albicans) identification directly from patient blood sample using ASTrID. ID results were confirmed using traditional methods.

Signal response from a multiplexed assay.

Of the approximately 500 clinical samples collected 28 identified as positive in normal clinical routine diagnostics were selected and are presented here. Pathogen ID was performed in a prototype ASTrID system, using a panel of 30 targets including 26 specific pathogens, 3 resistance markers and one pathogen group. Identification directly from patient without waiting for a positive blood culture achieved sensitivity of 97% and specificity of 99.6%, compared to conventional analysis on positive blood cultures.